Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants

Abstract SAR443820 (DNL788) is a selective, orally bioavailable, brain penetrant inhibitor of receptor‐interacting serine/threonine protein kinase 1 (RIPK1). This phase I first‐in‐human healthy participant study (NCT05795907) was comprised of three parts: randomized, double‐blind, placebo‐controlled...

Full description

Bibliographic Details

Published in:	Clinical and Translational Science
Main Authors:	Agnes Hincelin‐Mery, Xavier Nicolas, Cathy Cantalloube, Robert Pomponio, Pascale Lewanczyk, Myriam Benamor, Dimitry Ofengeim, Emmanuel Krupka, Jennifer Hsiao‐Nakamoto, Amy Eastenson, Nazem Atassi
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Online Access:	https://doi.org/10.1111/cts.13690